Woodline Partners LP Madrigal Pharmaceuticals, Inc. Transaction History
Woodline Partners LP
- $17.6 Billion
- Q2 2025
A detailed history of Woodline Partners LP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 159,623 shares of MDGL stock, worth $68.2 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
159,623
Previous 317,433
49.71%
Holding current value
$68.2 Million
Previous $105 Million
54.05%
% of portfolio
0.27%
Previous 0.73%
Shares
10 transactions
Others Institutions Holding MDGL
# of Institutions
362Shares Held
23.3MCall Options Held
738KPut Options Held
473K-
Janus Henderson Group PLC London, X02.19MShares$937 Million0.34% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.09MShares$893 Million32.86% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$852 Million9.27% of portfolio
-
Baker Bros. Advisors LP New York, NY1.98MShares$845 Million6.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.88MShares$803 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $7.31B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...